Rhumbline Advisers Oncternal Therapeutics, Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.28 - $0.79 $14 - $39	50 New	50 $0
Q2 2022 Aug 11, 2022	SELL	$0.7 - $1.56 $36,628 - $81,630	-52,327 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.37 - $2.43 $3,651 - $6,475	-2,665 Reduced 4.85%	52,327 $73,000
Q4 2021 Feb 10, 2022	SELL	$2.27 - $4.39 $642 - $1,242	-283 Reduced 0.51%	54,992 $125,000
Q3 2021 Nov 12, 2021	BUY	$3.37 - $4.76 $4,657 - $6,578	1,382 Added 2.56%	55,275 $230,000
Q2 2021 Aug 05, 2021	BUY	$4.75 - $9.39 $255,991 - $506,055	53,893 New	53,893 $256,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.